In short
Clinical trials are investigating Xxb750 in people with heart failure. The study looks at whether different doses can improve a heart failure blood marker and help define the best dose. It focuses on symptomatic patients with left ventricular ejection fraction below 50% who are already on standard treatment.
Key points
- Xxb750 is being studied in a Phase 2 clinical trial for people with symptomatic heart failure. The study is testing three target dose levels against placebo to see whether Xxb750 can reduce NT-proBNP, a blood marker linked to heart failure. It includes patients with left ventricular ejection fraction below 50%. The trial also aims to understand the dose-response relationship, which means how different doses may lead to different effects. The study was completed and enrolled 740 participants.
Trial overview
The main trial in the source data was a Phase 2 study of Xxb750 in patients with heart failure.
It was described as a proof-of-concept and dose-finding study, which means it was designed to see whether the treatment may work and to help choose the best dose for future research.
The trial was completed and enrolled 740 people.
Who was studied
The study focused on people with symptomatic heart failure, meaning they had heart failure with noticeable symptoms.
It included patients with left ventricular ejection fraction below 50%, which means the left side of the heart was pumping below a normal level.
Participants were already receiving standard of care, including an ACEI, an ARB, or sacubitril/valsartan.
What the study tested
The study compared three target dose levels of Xxb750 with placebo.
A placebo is a look-alike treatment that does not contain the active study medicine and is used to make the comparison fair.
The source data also lists several background heart medicines used in the study setting, including lisinopril, candesartan, valsartan, losartan, and others in the ACEI and ARB classes, along with valsartan and sacubitril.
Main endpoint
The main outcome was the change in log NT-proBNP from baseline to Week 16.
NT-proBNP is a blood marker that can help show how active or severe heart failure is.
“Baseline” means the start of the study, and Week 16 means the measurement was checked after 16 weeks of treatment.
Trial design and treatment groups
This was an interventional trial, which means researchers gave study treatment and followed the results.
The intervention list shows Xxb750 given by subcutaneous injection and compared with placebo, with the study using target dose levels to explore dose response.
Dose response means checking whether different doses lead to different effects.
What the results were meant to show
The study was built to evaluate whether Xxb750 could reduce NT-proBNP more than placebo in symptomatic heart failure patients.
It was also meant to show whether one of the tested doses looked better than the others, which can help guide later trials.
Because only one completed trial was provided, the source data mainly describes the study goal, patient group, phase, and endpoint rather than final results.